Torrent Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 235.00 Cr
- Paid Up Capital ₹ 169.22 Cr
- Company Age 52 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6,041.39 Cr
- Satisfied Charges ₹ 5,888.33 Cr
- Revenue Growth 11.96%
- Profit Growth 6.05%
- Ebitda 17.35%
- Net Worth 1.74%
- Total Assets 15.42%
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Ltd (TPL) was founded in India on 15 July 1972 and has a glorious history of 52 years and seven months. Its registered office is in Ahmedabad, Gujarat.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 500420 and on the National Stock Exchange(NSE) under TORNTPHARM.
The Corporate was formerly known as Torrent Pharmaceuticals Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 235.00 Cr and a paid-up capital of Rs 169.22 Cr.
The company currently has active open charges totaling ₹6,041.39 Cr. The company has closed loans amounting to ₹5,888.33 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Torrent Pharmaceuticals Ltd India are Sudhir Menon as CFO and Chintan Trivedi as Company Secretary. Nikhil Nirvan, Manish Choksi, Samir Mehta, and Five other members serve as directors at the Company.
Company Details
- Location Ahmedabad, Gujarat
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
L24230GJ1972PLC002126
-
Company No.
002126
-
Stock Symbol
BSE : 500420 NSE : TORNTPHARM
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
15 Jul 1972
-
Date of AGM
07 Aug 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Listed
-
ROC Code
Roc Ahmedabad
Industry
What products or services does Torrent Pharmaceuticals Ltd offer?
Torrent Pharmaceuticals Ltd offers a wide range of products and services, including Anti Infective Drugs & Medicines, Anti Infective Agent, Ayurvedic & Herbal Health Supplement, Herbal Sexual Health Supplement, Common Disease Medicines, Steroid, Pharmaceutical Services, Inspection & Quality Check Services, Quality Inspection Service, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Torrent Pharmaceuticals?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Samir Mehta
![]() |
Managing Director | 01-Aug-2010 | Current |
Sudhir Menon
![]() |
CFO | 01-Sep-2018 | Current |
Chintan Trivedi | Company Secretary | 01-Aug-2022 | Current |
Board Members (7)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Manish Choksi
![]() |
Director | 29-Jul-2022 | Current |
Nikhil Nirvan
![]() |
Director | Current | |
Ameera Shah
![]() |
Director | 02-Aug-2018 | Current |
Jinesh Shah
![]() |
Director | 01-Aug-2019 | Current |
Nayantara Bali
![]() |
Director | 07-Mar-2019 | Current |
Aman Mehta
![]() |
Whole-Time Director | 01-Aug-2022 | Current |
Financial Performance of Torrent Pharmaceuticals.
Torrent Pharmaceuticals Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 11.96% increase. The company also saw a slight improvement in profitability, with a 6.05% increase in profit. The company's net worth moved up by a moderate rise of 1.74%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Torrent Pharmaceuticals?
In 2023, Torrent Pharmaceuticals had a promoter holding of 71.25% and a public holding of 28.73%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹6,041.39 Cr
₹5,888.33 Cr
Charges Breakdown by Lending Institutions
- Idbi Trusteeship Services Limited : 3100.00 Cr
- Hdfc Bank Limited : 1350.00 Cr
- The Hongkong And Shanghai Banking Corporation Limited : 595.00 Cr
- Others : 550.00 Cr
- Axis Bank Limited : 300.00 Cr
- Others : 146.39 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
30 May 2023 | The Hongkong And Shanghai Banking Corporation Limited | ₹145.00 Cr | Open |
10 May 2023 | The Hongkong And Shanghai Banking Corporation Limited | ₹400.00 Cr | Open |
24 Feb 2023 | Hdfc Bank Limited | ₹350.00 Cr | Open |
07 Feb 2023 | Idbi Trusteeship Services Limited | ₹500.00 Cr | Open |
02 Apr 2022 | Hdfc Bank Limited | ₹450.00 Cr | Open |
How Many Employees Work at Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a workforce of 14520 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Torrent Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Torrent Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.